Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Mammaprint Stories

2014-04-09 16:25:20

DUBLIN, April 9, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/k3xnm6/molecular) has announced the addition of the "Molecular Diagnostics in Cancer Testing" [http://www.researchandmarkets.com/research/k3xnm6/molecular ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and...

2014-04-08 13:04:46

Trial identifies breast cancer patients likely to benefit from experimental drug In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer. Additionally, researchers learned that an algorithm used in the adaptive, randomized trial known as I-SPY 2 was highly effective at predicting the success of the treatment regimen in the...

2014-04-02 20:22:25

DUBLIN, April 3, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/fz82h5/biomarkers ) has announced the addition of the "Biomarkers: Discovery Techniques and Applications - A Global Market Overview" [http://www.researchandmarkets.com/research/fz82h5/biomarkers ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The potential offered by biomarkers in shaping the outcomes of clinical trials,...

2014-03-09 23:00:57

The rapid growth of the Cancer Profiling Market is attributed to its promising application in personalized cancer therapy; and its extension in early diagnosis, disease prognosis, and research applications will further enhance its market growth - http://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html. (PRWEB) March 09, 2014 The "Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research),...

2013-12-12 10:49:59

Genetic signature identifies patients with more aggressive triple-negative cancers A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment. The test, described in the Dec. 11 issue of PLOS ONE, was able to distinguish between patients with a good or poor prognosis, even within groups of patients already stratified by existing tests such as MammaPrint and...

2013-12-04 08:29:39

Conference Marks 10th Anniversary of Oncotype DX® Validation Study Presentation Representing a Decade of Determination in Eliminating 'One-Size-Fits-All' Approach to Breast Cancer Treatment REDWOOD CITY, Calif., Dec. 4, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from multiple Oncotype DX® breast cancer test studies at the 36(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), being held December 10-14, 2013 at...

2013-11-07 23:03:39

Reportbuyer.com just published a new market research report: Molecular Biomarkers for Cancer Detection and Management. London (PRWEB) November 07, 2013 New to Insight Pharma Reports is Molecular Biomarkers for Cancer Detection and Management: Technologies, Markets, and Trends. This report focuses on recent progress and new directions in this highly dynamic diagnostic field. Covering extensive background and history, commercialization, and marketing trends of cancer biomarker technologies,...

2013-09-30 23:34:30

Cancer/Tumor Profiling Market report categorizes the global cancer/tumor profiling market into geography, applications, technologies, and segment types. http://www.marketsandmarkets.com/Market-Reports/cancer-tumor-profiling-market-1250.html (PRWEB) September 30, 2013 The "Cancer/Tumor Profiling Market [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics,...

2013-09-26 08:27:11

DALLAS, September 26, 2013 /PRNewswire/ -- The "CANCER/TUMOR PROFILING MARKET [Applications (Personalized Medicine, Diagnostics, Biomarker Discovery, Prognosis, Research), Technologies (NGS, QPCR, IHC, FISH/CISH, Microarray), Segments: Genomics, Proteomics, Metabolomics, Epigenetics)] 2013 - 2018", report analyzes and studies the major market drivers, restraints, and adoption potential in North America, Europe, Asia, and Rest of the World. Browse market 22 data tables...

2013-09-09 16:23:45

Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, Calif. and AMSTERDAM, Sept. 9, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, today announced that multiple established international breast cancer treatment guidelines confirmed that Agendia's MammaPrint(®) tests, the leading product in Agendia's Symphony suite of breast cancer tests, significantly augment prognostic and predictive information in making key cancer...